UTHSC Houston, Dermatology Clincial Research Center
Welcome,         Profile    Billing    Logout  
 3 Trials 
7 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Hebert, Adelaide A
ADorable-1, NCT05559359: A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis

Recruiting
3
360
Europe, Canada, Japan, US, RoW
Lebrikizumab, LY3650150, DRM06, Placebo, Topical Corticosteroid (TCS)
Eli Lilly and Company, Dermira, Inc.
Atopic Dermatitis, Eczema
02/26
02/27
TAK-279-PsO-3003, NCT06550076: A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis

Recruiting
3
1300
Europe, Canada, Japan, US, RoW
TAK-279
Takeda
Plaque Psoriasis
05/26
05/26
TAK-279-3002, NCT06108544: A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period

Active, not recruiting
3
1108
Europe, Canada, US, RoW
TAK-279, Placebo, Apremilast
Takeda
Plaque Psoriasis
12/24
11/25
ADorable-2, NCT05735483: A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis

Enrolling by invitation
3
310
Europe, Canada, Japan, US, RoW
Lebrikizumab, LY3650150, Placebo
Eli Lilly and Company
Atopic Dermatitis, Eczema
06/26
06/26
AMETHYST, NCT05531565 / 2020-000727-40: A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus

Recruiting
2/3
474
Europe, Canada, Japan, US, RoW
Litifilimab, BIIB059, Placebo
Biogen, Biogen Idec Research Limited
Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus
10/26
12/27
NCT06504160: Targeted Investigation of Microbiome 2 Treat Atopic Dermatitis (TIME-2)

Not yet recruiting
2
86
US
ShA9 Topical Gel, Hydrocortisone Ointment, Clobetasol Ointment, Fluocinonide Ointment, Placebo (Vehicle) Topical Gel
National Institute of Allergy and Infectious Diseases (NIAID), Atopic Dermatitis Research Network (ADRN), Rho Federal Systems Division, Inc., PPD, Thermo Fisher Scientific Inc.
Atopic Dermatitis
06/26
07/26
NCT05414266: Study Evaluating Efficacy of Topical Squaric Acid Dibutyl Ester in Children and Adolescents With Alopecia Areata

Recruiting
1
36
US
Placebo, SADBE 5%
The University of Texas Health Science Center, Houston
Alopecia Areata
06/23
05/24

Download Options